Immunological mechanism underlying the immune response to recombinant human protein therapeutics

Trends in Pharmacological Sciences

Volumn 31, Issue 2, 2010, Pages 53-59

  Sauerborn, Melody ^a   Brinks, Vera ^a   Jiskoot, Wim ^b   Schellekens, Huub ^a,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; DRUG ANTIBODY; INSULIN; INSULIN ANTIBODY; INTERFERON BETA SERINE; POLYSORBATE 80; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL MATURATION; DIABETES MELLITUS; DRUG FORMULATION; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PURE RED CELL ANEMIA; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES; B-LYMPHOCYTES; ERYTHROPOIETIN; HUMANS; INSULIN; LYMPHOCYTE ACTIVATION; RECOMBINANT PROTEINS; THYMUS GLAND;

EID: 75149132833     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2009.11.001     Document Type: Article

References (50)

1. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. Drug Discov. 1 (2002) 457-462
2. Sorensen P.S., et al. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?. Mult. Scler. 14 (2008) 837-842
3. Macdougall I.C. Epoetin-induced pure red cell aplasia: diagnosis and treatment. Curr. Opin. Nephrol. Hypertens. 16 (2007) 585-588
4. Musso R. Efficacy and safety of recombinant factor VIII products in patients with hemophilia A. Drugs Today (Barc.) 44 (2008) 735-750
5. Hurwitz B.J. Important sources of variability in clinical studies of neutralizing antibodies against interferon beta. J. Neurol. Sci. 272 (2008) 8
6. Merad M., and Manz M.G. Dendritic cell homeostasis. Blood 113 (2009) 3418-3427
7. Martin-Fontecha A., et al. Dendritic cell migration to peripheral lymph nodes. Handb. Exp. Pharmacol. 188 (2009) 31-49
8. Valitutti S. Immunological synapse: center of attention Again. Immunity 29 (2008) 384
9. Yuseff M.I., et al. Dynamics of membrane trafficking downstream of B and T cell receptor engagement: impact on immune synapses. Traffic 10 (2009) 629-636
10. Tsourkas P.K., et al. Mechanisms of B-cell synapse formation predicted by Monte Carlo simulation. Biophys. J. 92 (2007) 4196-4208
11. Ruprecht C.R., and Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur. J. Immunol. 36 (2006) 810-816
12. Tangye S.G., and Tarlinton D.M. Memory B cells: effectors of long-lived immune responses. Eur. J. Immunol. 39 (2009) 2065-2075
13. Mond J.J., et al. T cell independent antigens. Curr. Opin. Immunol. 7 (1995) 349-354
14. Lange H., et al. Thymus-independent type 2 antigen induces a long-term IgG-related network memory. Mol. Immunol. 45 (2008) 2847
15. Obukhanych T.V., and Nussenzweig M.C. T-independent type II immune responses generate memory B cells. J. Exp. Med. 203 (2006) 305-310
16. Snapper C.M., and Mond J.J. A model for induction of T cell-independent humoral immunity in response to polysaccharide antigens. J. Immunol. 157 (1996) 2229-2233
17. Gao N., et al. Requirements for the natural killer cell-mediated induction of IgG1 and IgG2a expression in B lymphocytes. Int. Immunol. 20 (2008) 645-657
18. Peces R., et al. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N. Engl. J. Med. 335 (1996) 523-524
19. Bennett C.L., et al. Pure red-cell aplasia and epoetin therapy. N. Engl. J. Med. 351 (2004) 1403-1408
20. Schellekens H., and Jiskoot W. Eprex-associated pure red cell aplasia and leachates. Nat. Biotechnol. 24 (2006) 613-614
21. Mueller R., et al. Evaluation of the immuno-stimulatory potential of stopper extractables and leachables by using dendritic cells as readout. J. Pharm. Sci. 98 (2009) 3548-3561
22. Hermeling S., et al. Micelle-associated protein in epoetin formulations: a risk factor for immunogenicity?. Pharm. Res. 20 (2003) 1903-1907
23. Schellekens H., and Jiskoot W. Erythropoietin-associated PRCA: still an unsolved mystery. J. Immunotoxicol. 3 (2006) 123-130
24. Greenfield J.R., et al. Severe insulin resistance due to anti-insulin antibodies: response to plasma exchange and immunosuppressive therapy. Diabet. Med. 26 (2009) 79-82
25. Radermecker R.P., et al. Circulating insulin antibodies: influence of continuous subcutaneous or intraperitoneal insulin infusion, and impact on glucose control. Diabetes Metab. Res. Rev. 25 (2009) 491-501
26. Jaeger C., et al. Binding characteristics and crossreactivity of insulin autoantibodies and insulin antibodies directed to three different insulin molecules. Acta Diabetol. 45 (2008) 191-194
27. Fineberg S.E., et al. Immunological responses to exogenous insulin. Endocr. Rev. 28 (2007) 625-652
28. Rio J., et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann. Neurol. 59 (2006) 344-352
29. Farrell R., et al. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of interferon-beta. Mult. Scler. 14 (2008) 212-218
30. Kagawa Y., et al. Comparative study of the asparagine-linked sugar chains of natural human interferon-beta 1 and recombinant human interferon-beta 1 produced by three different mammalian cells. J. Biol. Chem. 263 (1988) 17508-17515
31. Hermeling S., et al. Development of a transgenic mouse model immune tolerant for human interferon beta. Pharm. Res. 22 (2005) 847-851
32. Bertolotto A., et al. Immunogenicity of interferon beta: differences among products. J. Neurol. 251 Suppl. 2 (2004) II15-II24
33. Runkel L., et al. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm. Res. 15 (1998) 641-649
34. Hermeling S., et al. Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 21 (2004) 897-903
35. Rosenberg A.S. Effects of protein aggregates: an immunologic perspective. AAPS J. 8 (2006) E501-E507
36. Hermeling S., et al. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J. Pharm. Sci. 95 (2006) 1084-1096
37. Kessler M., et al. Immunogenicity of biopharmaceuticals. Nephrol. Dial. Transplant. 21 Suppl. 5 (2006) v9-v12
38. Weiss IV W.F., et al. Principles, approaches, and challenges for predicting protein aggregation rates and shelf life. J. Pharm. Sci. 98 (2009) 1246-1277
39. Hinton H.J., et al. Pattern recognition by B cells: the role of antigen repetitiveness versus Toll-like receptors. Curr. Top. Microbiol. Immunol. 319 (2008) 1-15
40. Vos Q., et al. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol. Rev. 176 (2000) 154-170
41. Gibbs E., and Oger J. The IgG subclass-specificities of anti-IFNbeta antibodies change with time and differ between the IFNbeta products in relapsing remitting multiple sclerosis patients. J. Neuroimmunol. 190 (2007) 146-150
42. Weill J.C., et al. Human marginal zone B cells. Annu. Rev. Immunol. 27 (2009) 267-285
43. Scheeren F.A., et al. T cell-independent development and induction of somatic hypermutation in human IgM+ IgD+ CD27+ B cells. J. Exp. Med. 205 (2008) 2033-2042
44. Moens L., et al. Human memory B lymphocyte subsets fulfill distinct roles in the anti-polysaccharide and anti-protein immune response. J. Immunol. 181 (2008) 5306-5312
45. Krumbholz M., et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 131 (2008) 1455-1463
46. Mackay F., and Schneider P. Cracking the BAFF code. Nat. Rev. Immunol. 9 (2009) 491-502
47. Onda M. Reducing the immunogenicity of protein therapeutics. Curr. Drug Targets 10 (2009) 131-139
48. Ross C., et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann. Neurol. 48 (2000) 706-712
49. Hoffmann S., et al. HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am. J. Hum. Genet. 83 (2008) 219-227
50. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol. Dial. Transplant. 20 (2005) 3-9